Loading clinical trials...
Loading clinical trials...
A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy.
Conditions
Interventions
ZD6474 (vandetanib) 100mg
pemetrexed
+1 more
Start Date
July 1, 2005
Primary Completion Date
May 1, 2006
Completion Date
October 1, 2011
Last Updated
August 25, 2016
NCT04929028
NCT03647358
NCT07061964
NCT07042295
NCT03191149
NCT05039801
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions